Forum Topics GLP-1
Chagsy
3 months ago

There is a free episode of the podcast money talks by the economist on the subject of GLP-1 inhibitors:

https://podcasts.apple.com/au/podcast/money-talks-from-economist-radio/id420929545?i=1000652881427

Fascinating stuff.

No direct input to the RESMED thesis, but worth listening to for the expected timeline in increased adoption.

C

11
mikebrisy
3 months ago

@Chagsy agreed. Listened to it earlier this weekend.

Thinking about it through the $RMD lens ... (and I appreciate it's a much bigger deal than OSA) ... my main takeaway is that with all the research now focused on GLP-1's, over the coming years prices will fall. One advantage at the moment for $RMD, even in the event that GLP-1 aren't complementary to CPAP and do evenutally displace some of the demand (not my current thesis), is that they are significantly more costly which is a barrier to adoption as reimbursement isn't widely available. Over time, as prices fall with new chemical entities joining the line-up increasing competition, the economic moat will be eroded. Just another factor to keep an eye on.

10
GazD
3 months ago

Hate to be a pedant but they’re GLP-1 agonists @Chagsy and I will definitely have a listen so thanks for the link! Interesting stuff and so hot right now!


still think the resmed effect was a massive overreaction but time will tell.

FWIW my clinical experience (very limited) is that they work (which we already knew) but are associated with plenty of side effects

9
Remorhaz
8 months ago

An interesting (42 min) discussion on this month's episode of Magellan – In The Know podcast (available on all the normal podcast platforms as well as their youtube channel):

https://www.magellangroup.com.au/podcast/

https://www.youtube.com/watch?v=1cnGxq3duqQ

The world is awash with news that a drug designed to treat type 2 diabetes has also been approved to help achieve weight loss. Glucagon-like peptide 1 — or GLP-1 — is considered by some as a wonder drug and a new weapon in the public health battle against obesity. But what are the wider implications for the investment world?

In this episode of Magellan In The Know, Portfolio Manager Nikki Thomas is joined by three Magellan Investment Analysts: Emma Henderson, Wilson Nghe and Tracey Wahlberg. Together they discuss the investment landscape surrounding GLP-1, looking at the pitfalls and potential financial benefits for sectors from healthcare, food retailing and restaurants to fashion, exploring which parts of the consumption landscape could be winners or losers

All of the first half of the podcast mostly talks about the potential for impacts on the food and restaurant industry, but at the half way point they turn their attention to the healthcare space

10
Remorhaz
7 months ago

Magellan have provided a follow on (15 min) update to this - Magellan – In The Know podcast (available on all the normal podcast platforms as well as their youtube channel):

Special Bonus Episode: Insights from the US: An update on the Impacts of GLP-1 on healthcare systems

https://www.magellangroup.com.au/podcast/

https://www.youtube.com/watch?v=01znVB2t2ac

In this special 15 minute episode of Magellan In The Know, Portfolio Manager Nikki Thomas is joined by Investment Analyst Wilson Nghe, providing an update on GLP-1 following our recent episode on the weight loss wonder drug. Recently returned from the US, Wilson spoke with commercial players and policy makers on how they will approach reimbursements, which could be one of the biggest drivers to accelerate demand. They also discuss the future of care delivery in the US healthcare system


10
GazD
7 months ago

I’ll definitely have a listen to this. Best coverage I’ve heard regarding Resmed around this was Emma Fisher (Airlie I think) who made the point that OSA is, for a very a significant minority, unrelated to weight. This aside the case that GLP1s will significantly detract from the CPAP market is far from proven (even for the obese). I think this is a buying opportunity given the hype and am certainly a happy holder of Resmed IRL after buying in over the last 3/

13